Community Research and Development Information Service - CORDIS


This paper proposes the utilisation of 225Ac for the alpha-radioimmunotherapy of cancer. The isotope decays with a radioactive half-life of 10 days into a cascade of short-lived alpha- and beta-emitting isotopes. In addition, when indicated by the pharmacokinetic requirements of particular clinical applications, 213Bi, with a radioactive half-life of 47 min, can be chosen as an alternative source of alpha-particles in radioimmunotherapy. This isotope is the last alpha emitter in the 225Ac decay cascade and can be extracted from a 225Ac source at the bedside of the patient. 225Ac can be obtained quasi ad infinitum from one of its precursors, 229Th. The indications for the use of alpha-particles as an alternative to more traditional classes of radiation are derived from the particle-kinetic characteristics and the radioactive half-life of their source isotope, as well as from the properties of the target-selective carrier moiety for the source isotope.

Additional information

Authors: GEERLINGS M W, Akzo nv, Arnhem (NL);KASPERSEN F M, Organon International bv, Oss (NL);APOSTOLIDIS C, JRC Karlsruhe (DE);VAN DER HOUT R, Akzo Research Laboratories, Arnhem (NL)
Bibliographic Reference: Article: Nuclear Medicine Communications (1993) No. 14, pp. 121-125
Record Number: 199311224 / Last updated on: 1994-11-29
Original language: en
Available languages: en